CRISPR and Gene Editing: A Game-Changer in Drug Development

IF 2.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current pharmaceutical design Pub Date : 2024-04-05 DOI:10.2174/0113816128298080240328053845

Abhishek Verma, Tarun Sharma, Ankit Awasthi

{"title":"CRISPR and Gene Editing: A Game-Changer in Drug Development","authors":"Abhishek Verma, Tarun Sharma, Ankit Awasthi","doi":"10.2174/0113816128298080240328053845","DOIUrl":null,"url":null,"abstract":": CRISPR and gene editing technologies have emerged as transformative tools in medicine, offering unprecedented precision in targeting genetic disorders and revolutionizing drug development. This review explores the multifaceted impact of CRISPR across various medical domains, from hereditary diseases to infectious diseases and cancer. The potential of CRISPR in personalized medicine, therapeutic innovation, and pandemic prevention is highlighted, along with its role in reshaping traditional drug development processes. However, alongside its promise, ethical considerations loom large, particularly regarding germline editing and equitable access to treatments. The commercialization of CRISPR poses further challenges, raising questions about affordability and healthcare equity. Collaboration among scientists, policymakers, and the public is emphasized to navigate the ethical and societal implications of CRISPR responsibly. As the field advances, it is essential to ensure that the benefits of CRISPR are realized while addressing potential risks and maintaining a commitment to the well-being of future generations.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":"2014 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128298080240328053845","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

: CRISPR and gene editing technologies have emerged as transformative tools in medicine, offering unprecedented precision in targeting genetic disorders and revolutionizing drug development. This review explores the multifaceted impact of CRISPR across various medical domains, from hereditary diseases to infectious diseases and cancer. The potential of CRISPR in personalized medicine, therapeutic innovation, and pandemic prevention is highlighted, along with its role in reshaping traditional drug development processes. However, alongside its promise, ethical considerations loom large, particularly regarding germline editing and equitable access to treatments. The commercialization of CRISPR poses further challenges, raising questions about affordability and healthcare equity. Collaboration among scientists, policymakers, and the public is emphasized to navigate the ethical and societal implications of CRISPR responsibly. As the field advances, it is essential to ensure that the benefits of CRISPR are realized while addressing potential risks and maintaining a commitment to the well-being of future generations.

查看原文本刊更多论文

CRISPR 和基因编辑：改变药物开发的游戏规则

:CRISPR和基因编辑技术已成为医学领域的变革性工具，为靶向遗传疾病提供了前所未有的精确性，并为药物开发带来了革命性的变化。这篇综述探讨了 CRISPR 在从遗传疾病到传染病和癌症等各个医学领域的多方面影响。文章强调了 CRISPR 在个性化医疗、治疗创新和大流行病预防方面的潜力，以及它在重塑传统药物开发流程方面的作用。然而，除了它的前景，伦理方面的考虑也很重要，特别是关于种系编辑和公平获得治疗的问题。CRISPR 的商业化带来了更多的挑战，引发了关于可负担性和医疗保健公平性的问题。要负责任地驾驭 CRISPR 的伦理和社会影响，科学家、决策者和公众之间的合作至关重要。随着该领域的不断进步，必须确保实现 CRISPR 的益处，同时应对潜在风险，并继续致力于后代的福祉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.